GPR119 agonists for the treatment of type 2 diabetes (Q28259606)

https://api.crossref.org/works/10.1517/13543770903153878

Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543770903153878

Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/13543770903153878

Type 2 diabetes: principles of pathogenesis and therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Type 2 diabetes: new genes, new understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Five stages of evolving beta-cell dysfunction during progression to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Diabetic retinopathy. A clinical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Pharmacotherapy for the treatment of patients with type 2 diabetes mellitus: rationale and specific agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

New hepatic targets for glycaemic control in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Modulation of glucocorticoid action and the treatment of type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Emerging therapeutic strategies for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Signal transduction of PACAP and GLP-1 in pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

G protein-coupled receptors and insulin secretion: 119 and counting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

GPR119: "double-dipping" for better glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

A gut feeling for obesity: 7TM sensors on enteroendocrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

High throughput screening technologies for direct cyclic AMP measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Identification of G protein-coupled receptor genes from the human genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543770903153878

10.1517/13543770903153878

21 January 2018

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19780700

1 reference

Consolidated OpenCitations Corpus – April 2017